

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

International Application. No.

International Filing Date

Priority Date Claimed

PCT/GB99/01777

June 4, 1999

June 6, 1998

Title of Invention: Morphine-6-Glucuronide Synthesis

Applicants For DO/EO/US: Philip James PARSONS; Richard Andrew EWIN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ The annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☒ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - a. ☒ Cover page of International Publication No. WO99/64480.
 - b. ☐ Copy of Notification of Missing Requirements.

U.S. APPLICATION NO. **09/700909** | INTERNATIONAL APPLICATION NO. | ATTORNEY DOCKET NUMBER
 PCT/GB99/01777 | 07203.0023

17. [X] The following fees are submitted: CALCULATIONS

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO.....\$860.00

International preliminary examination fee paid to
 USPTO (37 CFR 1.482).....\$690.00

No international preliminary examination fee paid to
 USPTO (37 CFR 1.482) but international search fee
 paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00

Neither international preliminary examination fee
 (37 CFR 1.482) nor international search fee
 (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,000.00

International preliminary examination fee paid to USPTO
 (37 CFR 1.482) and all claims satisfied provisions
 of PCT Article 33(1)-(4).....\$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than
 [] 20 [] 30 months from the earliest claimed priority date
 (37 CFR 1.492(e)). \$

Claims	Number Filed	Number Extra	Rate	
Total Claims	14-20=		X \$18.00	\$
Independent Claims	1- 3=		X \$80.00	\$
Multiple dependent claim(s) (if applicable)			+\$270.00	\$270.00
TOTAL OF ABOVE CALCULATIONS			=	\$1130.00
Reduction by 1/2 for filing by small entity, if applicable.				\$565.00
SUBTOTAL			=	\$565.00
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
TOTAL NATIONAL FEE			=	\$565.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).				\$
			\$40.00 per property	+
TOTAL FEES ENCLOSED			=	\$565.00
Amount to be				
refunded				\$
charged				\$

a. [X] A check in the amount of **\$565.00** to cover the above fees is enclosed.


b. [] Please charge my Deposit Account No. _____ in the amount of
 \$ _____

to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [X] The Commissioner is hereby authorized to charge any additional fees
 which may be required, or credit any overpayment to Deposit Account
 No. 06-0916. A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any other fees due under 37 C.F.R. §1.16
 or §1.17 during the pendency of this application to our Deposit Account No. 06-0916.

SEND ALL CORRESPONDENCE TO:
 Finnegan, Henderson, Farabow
 Garrett & Dunner, L.L.P.
 300 I Street, N.W.
 Washington, D.C. 20005-3315
 MSG/EFC/FPD/peg


 Ernest F. Chapman
 Reg. No. 25,961

Submitted: November 21, 2000

ART 34 AMDT

Morphine-6-Glucuronide Synthesis

The invention provides a novel method for synthesising Morphine-6-Glucuronide (M6G) and intermediates therefor.

Synthesis of M6G from 3-acetylmorphine and methyl 2- α -bromo-3,4,5-tri-O-acetylglucuronate is described by Lacy, C., *et al.* (*Tetrahedron Letters*, 36 (22), (1995), 3949-3950).


Hidetoshi, Y. *et al.*, (*Chemical and Pharmaceutical Bulletin*, JP, TOKYO, 16 (11), (1968), 2114-2119) describe synthesis of M6G by reaction of 3-acetyl-morphine with a bromo derivative of glucuronic acid to form a Methyl [3-acetylmorphin-6-yl-2,3,4-tri-O-acetyl- β -D-glucopyranosid] uronate intermediate which is subsequently hydrolysed to M6G.

WO 93/05057 discloses preparation of M6G by reaction of 3-acetyl morphine with methyl 1 α -bromo, 1-deoxy, 2,3,4-tri-O-acetyl D glucopyranuronate and subsequently hydrolysing the resulting intermediate to M6G.

In order to synthesise M6G the major problem to overcome is to obtain the glycoside linkage with very high β -selectivity since prior methods produce the α -anomer.


One method for obtaining high β -selectivity is to use trichloroimidate as the leaving group, as shown in WO 93/03051: Figure 1 (Salford Ultrafine Chemicals and Research Limited).

Orthoesters are simple to synthesise from their respective bromides¹. There is a reaction reported in the literature² between the glucuronate orthoester (2) and the sugar derivative (3) catalysed by lutidinium perchlorate³ (4) (Scheme 1).




Scheme 1

When this reaction was repeated with the *t*-butyl orthoacetate (5) and cyclohexanol (6 equivalents), the desired product (6) was isolated in 9% yield. Two other products also suggested that they were the desired product, but with the loss of one acetyl group, isolated in a combined yield of 43% (Scheme 2).



Scheme 2


When 1.2 equivalents of 4-*tert*-butylcyclohexanol was used, the desired compound (7) was obtained in 17% yield. Other compounds obtained from the reaction also appeared to contain the desired peaks in the nmr, but after further examination proved to be the product of transorthoesterification (8) (Scheme 3).



Scheme 3

Reaction of orthoester (5) with protected morphine

Initially, 1.2 equivalents of 3-TBS protected morphine and the orthoester (5) were dissolved in chlorobenzene and half of the solvent was distilled off before 0.1 equivalents of lutidinium perchlorate (4) in chlorobenzene was added. The solvent was continuously distilled off while fresh solvent was added, and after 2.5 h another compound was formed with similar tlc properties to the protected morphine. Workup and chromatography gave a compound which corresponded to trans-orthoesterified material (9). None of the desired material was obtained (Scheme 4).



Scheme 4


This product (9) was resubmitted to the reaction conditions (0.1 equivalents of lutidinium perchlorate and protected morphine in refluxing chlorobenzene) with no new products formed after 4h. Two further reactions were attempted using two equivalents of orthoester (5) and 0.2 equivalents of lutidinium perchlorate and 1 equivalent of orthoester (5) and 1.2 equivalents of lutidinium perchlorate, but both gave varying yields of orthoester (9).

We have concluded that a different, more bulky, alkyl group was needed on the orthoester to hinder attack there. Initially, the isopropyl group was examined. However, the initial reaction, perisobutyrylation, failed to give a compound which recrystallised from petrol, so the α and β anomers could not be separated. Therefore, attention focussed on the pivaloyl group.

The invention is further described with reference to the accompanying figure 2 which shows a summary of a reaction scheme according to the invention for synthesising M6G.


Synthesis of the Perpivalated Glucuronide

Synthesis of perpivalated glucuronide proved troublesome at first, giving a mixture of 3 and 4 non-pivalated material (scheme 5).

**Scheme 5**

A search through the literature revealed that glucose can be perpivalated by heating the reaction to reflux for 3h. and then stirring it for 7 days.

When this reaction was repeated on ring-opened glucurono-3,6-lactone (Scheme 6), perpivalated product (10) was obtained by crystallisation of the crude product from MeOH (or EtOH) and water and drying the crystals by dissolving them in DCM, separating any water present, drying, and then evaporating the organic layer to give the product in 29-52% yield, a substantial improvement on previous yields for this step.



Scheme 6


DMAP was added to aid perpivalation, although there has been no evidence to suggest that this is necessary. The variation in the yields quoted is probably due to the amount of MeOH left over from the first step. The high yield quoted (52%) was obtained by using 6 (instead of 5) equivalents of tBuCOCl. A slight

colouration of the final product proved no handicap in the next step, as after a silica plug and recrystallisation, pure white crystals were obtained.

Synthesis of the Orthoester (6)

Conversion of the perpivalated material (10) to the α -bromide (11) required gentle heating (to approximately 35° C) to dissolve the substrate in the reaction mixture. The reaction proceeded very cleanly by tlc analysis, showing a spot to spot conversion. Attempts to reduce the amount of HBr used to five equivalents led to incomplete conversion of the starting material, so 12 equivalents were used as before. The product was slowly crystallised from EtOH/water or MeOH/water to give long white crystals in a yield of 52-78%. High yields were always obtained when fresh HBr/AcOH was used. The crystals were dried by again dissolving them in dichloromethane, the water separated, and the organic layer dried and evaporated.


The orthoester (12) was obtained in 63-81% yield by stirring a 1:1 mixture of EtOH:collidine at 70° C (oil bath temperature) with the bromide (11) and 0.8 equivalents of Et₄NBr (Scheme 7). The product can easily be crystallised from EtOH/water or MeOH/water as white crystals, with a trace of collidine still present (detected by smell!) but which doesn't effect the next reaction. An interesting by-product from this reaction (obtained in about 10%) is the result of EtOH attacking the anomeric position to give the β -anomer (13). Again, the difficulty in drying the crystals meant that they were dissolved in petrol (40-60), the water separated, and the organic layer dried and evaporated.



Scheme 7

Synthesis of 3-Pivalated morphine (14)


Selective deprotonation of the phenolic OH of morphine was achieved using NaH (surprisingly, the anion turns out to be soluble in THF) and trimethylacetyl chloride was added dropwise to give the desired product after recrystallisation from MeOH/water (Scheme 8). Again, the difficulty in drying the crystals meant that they were dissolved in dichloromethane, the water separated, and the organic layer dried and evaporated to give a white powder in 81% yield.

**Scheme 8**

1.1 equivalents of trimethylacetyl chloride were used, but this led to some dipivalated morphine which proved difficult to recrystallise apart from mono-pivalated morphine (14) or the protected M6G (16). Thus, it would be advantageous in the future to use 1 equivalent of trimethylacetyl chloride.

Synthesis of Lutidinium Perchlorate (15)

This was achieved by simply adding aqueous perchloric acid to an ether solution of lutidine (excess, as this remains in the Et₂O layer) (Scheme 9) and evaporating the water until crystals form, which were collected by filtration.


**Scheme 9**

The crystals are deliquescent and thus need to be dried under high vacuum prior to use.

Other acid catalysts have been investigated in the coupling reaction below, but with no success. However, this compound has shown no tendencies to decompose, proving both thermal and shock stable, so shouldn't prove a problem on scale up.

Coupling of the orthoester (12) with 3-pivalated morphine (14)

Coupling the orthoester (12) to 1.1 equivalents of 3-pivalated morphine (14) was achieved by adding 0.1 equivalents of lutidinium perchlorate (15) every 15 min. until 1.2 equivalents had been added to the distilling chlorobenzene. The reaction was then stirred under reflux for a further 2h. to give a mixture of 3-pivalated morphine (14) protected M6G (16) and much less polar materials. Work-up and crude purification by chromatography gave protected M6G (16) and 3-pivalated morphine (14) which was purified by recrystallisation from MeOH/(water, small quantity) to give (16) in 29% yield (with no detectable quantity of α -anomer or trans-orthoesterified material from nmr analysis) (Scheme 10).




Scheme 10

This yield is the greatest amount obtained from this reaction and further improvements might be possible. Lutidinium perchlorate (15) was added every 15 min. as a solid appeared to crystallise from the reaction mixture (presumably the 3-pivalated morphine perchlorate) and, if no more catalyst is added, the major product turned out to be the trans-orthoesterified material (similar to orthoester (9) in Scheme 14). If 1.2 equivalents of lutidinium perchlorate (15) was added directly to the reaction, only 6% of coupled material was obtained (presumably as all the 3-pivalated morphine had been removed from the reaction as the

perchlorate salt). The main problem with adding the catalyst, is its insolubility in chlorobenzene lower than approximately 100° C. If it is possible on a large scale to add lutidinium perchlorate (15) in chlorobenzene at 100° C, this may prove not only simpler to add the catalyst, but also lead to increasing yields. The reaction also needs to be refluxed for an additional 2 hours after all the lutidinium perchlorate (15) has been added, to cause the trans-orthoesterified material to rearrange to the desired material.

Global Deprotection of Protected M6G (16)

Heating protected M6G (16) in MeOH until it dissolves before adding the water (which causes it to crystallise from the reaction mixture) and $\text{Ca}(\text{OH})_2$ seems to be the mildest way of performing this reaction. After stirring for 3 days, the reaction gave, by tlc analysis, M6G (17) and morphine (Scheme 11).




Scheme 11

The reaction was quite slow due to the insolubility of $\text{Ca}(\text{OH})_2$ in water, but when the reaction is deemed to have finished by tlc analysis, 6.5 equivalents of sulfuric acid were added or until the reaction reached pH 4. The CaSO_4 so formed was filtered off and the trimethylacetic acid also formed was removed by washing the filtrate with DCM. Evaporating the water proved the hardest part of this reaction due to excessive foaming. Some CaSO_4 remains in the filtrate and this was removed by adding MeOH to crystallise it out. The residue produced after all the water had been evaporated was purified by repeated washing with MeOH as M6G is virtually insoluble in MeOH while morphine is soluble in it. The morphine present in the crude residue probably arrived there due to the di-pivalated morphine passing through the coupling reaction and then being deprotected to morphine in this final step. Hopefully, by using strictly 1 equivalent of trimethylacetyl chloride, this should eliminate the di-pivalated morphine, thus make purification of M6G even simpler, and increasing the yield for the final step.

The invention is further described in detail below by way of example only.

Example 1

Methyl 1 β ,2,3,4-tetra-O-pivaloylglucuronate




Glucurono-6,3-lactone (147 g, 0.8 mol) was stirred as a suspension in methanol (1L, not dried) under nitrogen. A catalytic amount of sodium methoxide (147 mg, 2.6 mmol) was added to the suspension, and after 2 hours most of the suspension was still present. The reaction proceeded very slowly at room temperature, $\sim 18^{\circ}\text{C}$, but noticeably increased in rate when the reaction was warmed, therefore, the reaction was gently warmed to $\sim 25^{\circ}\text{C}$. After another hour of stirring, most of the suspension had dissolved to leave a clear yellow solution that was then evaporated. The residue was found to be a solid, which tended to foam under vacuum, which made total removal of all the methanol difficult. Chloroform (400mL), followed by 6 equivalents of pyridine (400mL, 4.8mol) and a catalytic amount of *N,N*-dimethyl-4-aminopyridine (4 g) was then added to the residue that slowly dissolved in this mixture. The solution was stirred using a magnetic stirrer plate and flea, but the problems encountered in continuously stirring this reaction would make an overhead mechanical stirrer preferable at this stage. The reaction was then cooled to 0°C and 5 equivalents of trimethylacetyl chloride (500mL, 4 mol) was added gradually, not allowing the reaction to warm to a temperature above $\sim 8^{\circ}\text{C}$. The yellow/orange solution became colourless on addition of the first portion of trimethylacetyl chloride, and after approximately half of the volume was added, a white precipitate was observed (pyr.HCl). After addition was complete, the reaction was stirred overnight at room temperature before being heated at reflux for 2 hours, during


which time the reaction turned black with the white precipitate still present. Tlc analysis showed that the desired product had been produced (R_f 0.5, 1:1 Et₂O:petrol), but some mono-protected material remained (R_f 0.3 and 2.8, 1:1 Et₂O:petrol). The reaction was then allowed to cool to room temperature over 3 hours, then further cooled to 0°C before methanol was added gradually (this quenches the excess trimethylacetyl chloride to give methyl trimethylacetate, which is evaporated off with the solvent). The black solution was then poured into a 2L separating funnel, and washed with water (600 mL), 1M HCl (2 * 600 mL), water (600 mL), and saturated aqueous NaHCO₃ (2 * 600 mL). The organic layer was then dried with MgSO₄ and passed through approximately 5cm of silica on a sinter funnel (which removed a black baseline compound). The silica was washed with dichloromethane (100 mL) and the combined filtrates evaporated to leave a black viscous oil, which was re-dissolved in ethanol (~1L) and had water added until the solution turned turbid (~500mL). More ethanol was added until the turbid solution cleared, and the solution was left to crystallise overnight. The yellow crystals were dissolved in dichloromethane (300 mL) and any excess water removed by separation, the dichloromethane layer was then dried and evaporated.

The white powder (113.5 g, 26%) was then used in the next reaction.

Methyl 1-deoxy-1- α -bromo,2,3,4-tri-O-pivaloylglucuronate




Methyl 1(β),2,3,4-tetra-O-pivaloylglucuronate (108.5 g, 0.2 mol) was dissolved in glacial acetic acid (500 mL) (with the aid of some gentle heating) and placed in a bath of cold water. 12 equivalents of 33% HBr in acetic acid (500 mL, 2.9 mol) were then added at a rate required to prevent the acetic acid freezing without the reaction exotherming too greatly. After the addition was complete, the reaction was allowed to warm to room temperature. If any white solid (starting material) persisted, gentle warming was applied to the reaction until it dissolved and the reaction then allowed to cool and stir overnight. The orange/brown solution was then cautiously poured into dichloromethane (500 mL) / water (500 mL), the organic layer separated, washed with water (500 mL) and saturated NaHCO_3 (500 mL) (with care to avoid too rapid an evolution of CO_2). The organic layer was then dried (MgSO_4) and passed through approximately 2 cm of silica, the silica was washed with more dichloromethane (50 mL) and the combined filtrates evaporated (taking care to remove all the dichloromethane). The residue was then dissolved in EtOH (~400 mL) and water added until the reaction turned turbid. More ethanol was added until the solution just turned clear and the product allowed to crystallise overnight which were collected by filtration. The crystals were dissolved in dichloromethane and the organic layer separated from any water that remained, dried (MgSO_4), and evaporated. The white powder (76 g, 72%) was then used in the next reaction.

Methyl 1 α ,2-ethylorthopivalate-3,4-di-O-pivaloylglucuronate

Methyl 1-deoxy-1- α -bromo-2,3,4-tri-O-pivaloylglucuronate (69 g, 0.13 mol) was dissolved in collidine (300 mL) (pre-dried by distilling onto activated 3Å sieves) and ethanol (300 mL) (pre-dried by distilling from NaOEt onto activated 3Å sieves). 0.8 equivalents of pre-dried tetraethylammonium bromide (22 g, 0.1 mol) was then added to the reaction, which was stirred at 60°C (oil-bath temperature 70°C) overnight. The reaction was then cooled and poured into dichloromethane (500 mL) / water (500 mL) and the organic layer separated, dried (MgSO_4), and evaporated. The collidine was removed by low-pressure distillation (total evaporation is not necessary), the residue dissolved in EtOH (~400mL), and water added until the product started to crystallise out. The white crystals were collected by filtration and dissolved in petrol. The organic layer was then separated from any water that remained, dried (MgSO_4), and evaporated.


The white powder (50g, 78%) was then used in the next reaction.

3'-O-Pivaloylmorphine

Morphine (12g, 42 mmol) was added portionwise to a THF (80 mL, Na dried) suspension of 1.05 equivalents of petrol washed NaH (60 % dispersion in oil, 1.768 g, 44 mmol) at 0° C. After stirring for 1h at room temperature, 1.1 equivalents of trimethylacetyl chloride (5.7 mL, 46 mmol) were added to the clear reaction mixture at 0° C and eventually a white solid precipitated from the reaction. After 1h., MeOH (10 mL) followed by saturated aqueous sodium bicarbonate (100 mL) were added to the reaction which was then extracted with Et₂O (2x200 mL). The combined extracts were washed with brine (200 mL), dried, and evaporated. The residue was recrystallised from MeOH/water and the crystals dissolved in dichloromethane and the organic layer separated from any water that remained, dried (MgSO₄), and evaporated.


The white powder (12.6 g, 81%) was then used in the next reaction.

Lutidinium Perchlorate




A 60% aqueous solution of perchloric acid (29 mL, 0.27 mol) was added to 1.1 equivalents of lutidine (34 mL, 0.29 mL) in Et_2O (250 mL) at 0°C . After stirring for 0.5h. at room temperature, the aqueous layer was separated and the water evaporated until a white solid crystallised from the water, the crystals filtered off and washed with Et_2O to give the product as a white crystalline solid (30 g, 54%). The product was dried under high vacuum prior to use.

Methyl 1 β -6'-O-(3'-O-pivaloylmorphine)-2,3,4-tri-O-pivaloylglucuronate



A chlorobenzene (400 mL) (distilled from CaH₂ onto activated 3Å sieves) solution of 1.1 equivalents of 3-O-pivaloyloxymorphine (8.49 g, 23 mmol) and methyl 1 α ,2-ethylorthopivalate-3,4-di-O-pivaloylglucuronate (10 g, 20 mmol) was heated to reflux to distil off approximately half of the solvent. 0.1 Equivalents of lutidinium perchlorate (415 mg, 2 mmol) was then added to the reaction that was still at reflux. The reaction was then stirred at reflux for 15 min with chlorobenzene continuously distilled off and fresh chlorobenzene added. After this time, a further 0.1 equivalents of lutidinium perchlorate (415 mg, 2 mmol) was then added to the reaction. This procedure was repeated every 15 min until 1.2 equivalents of lutidinium perchlorate (5.2 g, 25 mmol) had been added. The reaction was then stirred at reflux for 2 hours with chlorobenzene continuously distilled off and fresh chlorobenzene added. After this time, the reaction was allowed to cool and then poured into dichloromethane (500 mL) / water (500 mL), the organic layer separated, washed with saturated aqueous sodium bicarbonate (500 mL), dried, and evaporated. The residue, after some of the chlorobenzene had been removed under low pressure, was applied to the top of a silica column and eluted with diethyl ether to remove the non-polar by-products and then with 5% methanol in dichloromethane. The desired product was separated from 3-Piv-M by recrystallisation from MeOH/water to give a white crystalline powder (4.76 g, 29%).

Morphine-6-gluconoride




Methyl 1 β -6'-O-(3'-O-pivaloyloxymorphine)-2,3,4-tri-O-pivaloylglucuronate (3.06 g, 3.77 mmol) was dissolved in MeOH (60 mL) (with the help of some heating) and had water (7 mL) followed by 6.5 equivalents of calcium hydroxide (1.817 g, 24.5 mmol) added to it. The reaction was stirred for two days when water (60 mL) was added and the reaction stirred for a further day until the reaction was shown to be complete by tlc analysis (R_f 0.3, 45% nBuOH; 15% water; 20% acetone; 10% acetic acid; 10% of a 5% aqueous solution of ammonia). 6.5 equivalents of 0.25M aqueous sulphuric acid (98 mL, 24.5 mmol) were added (pH 4) and the reaction stirred for 1 hour. The reaction was then filtered to remove CaSO₄ and the solid washed with water (30 mL). The filtrate was then washed with DCM (2x100 mL), three quarters of the water evaporated and the same quantity of MeOH added. The white solid (mainly CaSO₄) was then filtered and the filtrate evaporated. The residue (1.56 g) had MeOH (100 mL) added and the white solid filtered and repeatedly washed with MeOH to give the desired compound (1.05 g, 60%) which could, according to the literature, be recrystallised from H₂O/MeOH (although this has not been performed on this material).

References

1. For a review of orthoesters and their synthetic applications see N. K. Kochetkov and A. F. Bochkov, *Recent Developments in the Chemistry of Natural Carbon Compounds*, Ed. R. Bognár, V. Bruckner, and Cs. Szántay, Akadémiai Kiadó: Budapest, 1971, vol. 4, p.77-191.
2. H. P. Wessel, L. Labler, and T. B. Tschopp, *Helv. Chim. Acta.*, 1989, **72**, 1268.
3. The use of 2,6-dimethylpyridinium perchlorate (4) was first reported by N. K. Kochetkov, A. F. Bochkov, T. A. Sokolovskaya, and V. J. Snyatkova, *Carbohydr. Res.*, 1971, **16**, 17.


Claims

1. A method for the preferential synthesis of the β -anomer of M6G which includes the step shown in Scheme 10:




Scheme 10

2. Synthesis according to claim 1 which includes the step shown in Scheme 7:



Scheme 7


3. Synthesis according to claim 1 or 2 which includes the step shown in Scheme 6:



Scheme 6


wherein use of DMAP is optional.

4. Synthesis according to any preceding claim which includes the step shown in scheme 8:




Scheme 8

5. Synthesis according to any preceding claim which includes the step shown in Scheme 9:



Scheme 9

6. Synthesis according to any preceding claim which includes a step to hydrolyse the protecting groups from compound 16.
7. Synthesis according to claim 6 in which the hydrolysis is as shown in Scheme 11:



Scheme 11

8. A compound of formula (12) as defined in claim 2 or a derivative thereof for use in a method according to claim 1.
9. Use of a compound of formula (10) as defined in claim 1 or a derivative thereof in a method according to claim 2.
10. Use of a compound of formula (11) as defined in claim 2 or a derivative thereof in a method according to claim 2.
11. Use of a compound of formula (14) as defined in claim 3 or a derivative thereof in a method according to claim 1.
12. Use of a compound of formula (15) as defined in claim 4 or a derivative thereof in a method according to claim 1.
13. Use of a compound of formula (16) as defined in claim 5 or a derivative thereof in a method according to claim 7.





Figure 1

Prior Art

Figure 2

A reaction scheme according to the invention for synthesising M6G



09/160909

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Morphine-6-Glucuronide Synthesis

the specification of which:

is attached hereto; or

was filed as United States Application Serial No. _____
on November 21, 2000; or

was filed as PCT International Application Number PCT/GB99/01777
on June 4, 1999.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s), designating at least one country other than the United States, listed below and have also identified below any foreign application(s) for patent or inventor's certificate, or any PCT international application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
Great Britain	9812097.5	June 6, 1998	X YES <input type="checkbox"/> NO
Great Britain	9900833.6	January 15, 1999	X YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT international application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)

69

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Reg. No. 22,540**, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Heffer, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilley, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewris, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Dirk D. Thomas, Reg. No. 32,600; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,043; Andrew Chanho Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; and Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 33,921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; and David A. Manspeizer, Reg. No. 37,540 and Please address all correspondence to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, 1300 I Street, N.W., Washington, D.C. 20005, Telephone No. (202) 408-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of first Inventor	Inventor's Signature	Date
Philip James PARSONS	<i>P. Parsons</i>	06/01/2001
Residence	Country of Citizenship	
Heathfield, East Sussex, Great Britain	Great Britain	
Post Office Address		
St. Margarets, Tilsmore Road, Heathfield, East Sussex TN21 0XT, Great Britain		

Full Name of Second Inventor	Inventor's Signature	Date
Richard Andrew EWIN	* Richard Ewin	15/1/01
Residence		Country of Citizenship
Brighton, <u>East Sussex</u> , Great Britain		Great Britain
Post Office Address		
Basement Flat, 6A College Terrace, Kemptown, Brighton, East Sussex, BN2 2EE, Great Britain		